In a Sept.16 letter to National Association of Boards of Pharmacy CEO Al Carter, FDA states that desiccated thyroid extract products can put patients at harm and that therapies containing DTE require a biologics license application. The letter encouraged NABP to share the letter with its members, the state boards of pharmacy. Carter relayed the information to boards of pharmacy on Sept. 22.